Cargando…

Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2

Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Juárez-Navarro, Karen J., Padilla-Camberos, Eduardo, Díaz, Néstor Fabián, Miranda-Altamirano, Ariel, Díaz-Martínez, N. Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769649/
https://www.ncbi.nlm.nih.gov/pubmed/33414832
http://dx.doi.org/10.1155/2020/8892189
_version_ 1783629372185378816
author Juárez-Navarro, Karen J.
Padilla-Camberos, Eduardo
Díaz, Néstor Fabián
Miranda-Altamirano, Ariel
Díaz-Martínez, N. Emmanuel
author_facet Juárez-Navarro, Karen J.
Padilla-Camberos, Eduardo
Díaz, Néstor Fabián
Miranda-Altamirano, Ariel
Díaz-Martínez, N. Emmanuel
author_sort Juárez-Navarro, Karen J.
collection PubMed
description Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals.
format Online
Article
Text
id pubmed-7769649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77696492021-01-06 Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 Juárez-Navarro, Karen J. Padilla-Camberos, Eduardo Díaz, Néstor Fabián Miranda-Altamirano, Ariel Díaz-Martínez, N. Emmanuel Stem Cells Int Review Article Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals. Hindawi 2020-12-18 /pmc/articles/PMC7769649/ /pubmed/33414832 http://dx.doi.org/10.1155/2020/8892189 Text en Copyright © 2020 Karen J. Juárez-Navarro et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Juárez-Navarro, Karen J.
Padilla-Camberos, Eduardo
Díaz, Néstor Fabián
Miranda-Altamirano, Ariel
Díaz-Martínez, N. Emmanuel
Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title_full Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title_fullStr Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title_full_unstemmed Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title_short Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
title_sort human mesenchymal stem cells: the present alternative for high-incidence diseases, even sars-cov-2
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769649/
https://www.ncbi.nlm.nih.gov/pubmed/33414832
http://dx.doi.org/10.1155/2020/8892189
work_keys_str_mv AT juareznavarrokarenj humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2
AT padillacamberoseduardo humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2
AT diaznestorfabian humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2
AT mirandaaltamiranoariel humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2
AT diazmartineznemmanuel humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2